You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
泰恩康(301263.SZ):子公司獲得孟魯司特鈉顆粒藥品註冊證書
格隆匯 05-27 16:35

格隆匯5月27日丨泰恩康(301263.SZ)公佈,公司全資子公司山東華鉑凱盛生物科技有限公司於近日收到國家藥品監督管理局簽發的孟魯司特鈉顆粒《藥品註冊證書》。

孟魯司特鈉是一種強選擇性白三烯受體拮抗劑,通過阻斷該受體而發揮抑制白三烯介導反應的作用,可抑制白三烯介導的一系列呼吸道反應。2002年7月26日,默沙東公司在美國首先上市孟魯司特鈉顆粒,商品名為SINGULAIR,規格為0.5g:4mg(以孟魯司特計);2005年孟魯司特鈉顆粒獲准進入我國,商品名為順爾寧。

孟魯司特鈉顆粒適用於1歲以上兒童哮喘的預防和長期治療,包括預防白天和夜間的哮喘症狀,治療對阿司匹林敏感的哮喘患者以及預防運動誘發的支氣管收縮,減輕過敏性鼻炎引起的症狀。

經查詢國家藥監局網站數據,截至目前,孟魯司特鈉顆粒在國內共有13家企業獲得藥品註冊批件。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account